Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to <6 years. In an open‐la...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Kathleen B., Rosenthal, Philip, Murray, Karen F., Honegger, Jonathan R., Hardikar, Winita, Hague, Rosie, Mittal, Naveen, Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Narkewicz, Michael R., Rao, Girish S., Whitworth, Suzanne, Bansal, Sanjay, Balistreri, William F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028138/
https://www.ncbi.nlm.nih.gov/pubmed/31220349
http://dx.doi.org/10.1002/hep.30830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028138/
https://www.ncbi.nlm.nih.gov/pubmed/31220349
http://dx.doi.org/10.1002/hep.30830

Ejemplares similares